|1.||Kokai-Kun, John F: 4 articles (07/2009 - 08/2005)|
|2.||Kerr, D E: 4 articles (03/2004 - 01/2001)|
|3.||Satishkumar, Rohan: 3 articles (12/2011 - 08/2011)|
|4.||Vertegel, Alexey: 3 articles (12/2011 - 08/2011)|
|5.||Heniford, B Todd: 3 articles (12/2011 - 08/2011)|
|6.||Chanturiya, Tanya: 3 articles (07/2009 - 02/2007)|
|7.||Kerr, David E: 3 articles (10/2005 - 10/2003)|
|8.||Wall, Robert J: 3 articles (10/2005 - 10/2003)|
|9.||Plaut, K: 3 articles (03/2004 - 01/2001)|
|10.||Bramley, A J: 3 articles (03/2004 - 01/2001)|
01/01/2014 - "In the current study we present the first application of the biofilm-penetrating antimicrobial peptide lysostaphin in the context of bone infections. "
12/01/2011 - "The goals of this study were to determine if LS adhered to porcine mesh (PM) can impact host survival, reduce the risk of long-term PM infection, and to analyze lysostaphin bound PM (LS-PM) mesh-fascial interface in an infected field. "
05/21/2015 - "In contrast, while wild-type lysostaphin was efficacious against the initial MRSA infection, it failed to clear subsequent bacterial challenges that were coincident with escalating anti-drug antibody titers. "
09/01/2014 - "These results demonstrate the controlled release of lysostaphin from HA/CS composites and their biocompatibility, suggesting the potential application of these composites to bone injury and infection applications."
01/01/2014 - "The presented approach of terminally sterilized lysostaphin-coated implants appears to be a promising therapeutic approach for low grade infection or as prophylactic strategy in high risk fracture care e.g. "
03/01/1992 - "A recombinant bactericidal protein, recombinant lysostaphin (r-lysostaphin), that may be useful as an intramammary therapeutic for Staphylococcus aureus mastitis in dairy cattle, was evaluated for immunogenicity to various hosts. "
12/01/1991 - "A recombinant mucolytic protein, lysostaphin, was evaluated as a potential intramammary therapeutic for Staphylococcus aureus mastitis in dairy cattle. "
10/01/2003 - "In the current study, we continue our assessment of lysostaphin as a suitable antimicrobial protein for mastitis resistance and have investigated mammary gland development and function in three lines of transgenic mice. "
01/01/2013 - "Lysostaphin (LYS) is an anti-staphylococcal prokaryotic polypeptide that has been used to avoid Staphylococcus aureus mastitis through transgenic or viral vector approaches exogenously expressed in dairy animals. "
04/01/2012 - "Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands."
01/01/2001 - "Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice."
01/01/2006 - "coli enables preparation of large quantity of r-lysostaphin for structure function studies and evaluation of its clinical potential in therapy and prophylaxis of staphylococcal infections."
05/01/2014 - "Lysostaphin represents a promising therapeutic agent for the treatment of staphylococcal infections, in particular those of methicillin-resistant Staphylococcus aureus (MRSA). "
08/01/2011 - "Lysostaphin-coated mesh prevents staphylococcal infection and significantly improves survival in a contaminated surgical field."
09/01/2008 - "Due to its unique specificity, lysostaphin could have high potential in the treatment of antibiotic-resistant staphylococcal infections. "
06/01/2001 - "Lysostaphin is effective in treating experimental endophthalmitis mediated by MRSA."
06/01/2001 - "Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit."
03/01/2006 - "The effectiveness of lysostaphin therapy was tested in an experimental model of endophthalmitis by intravitreally injecting log phase bacteria (100 colony-forming units; cfu) into rabbit eyes (n = 3 eyes per group). "
12/01/2002 - "A single intravitreous injection of lysostaphin (0.1%) sterilized all eyes of immunized and nonimmune rabbits with endophthalmitis. "
06/01/2001 - "To determine the effectiveness of lysostaphin treatment of experimental endophthalmitis caused by methicillin-resistant Staphylococcus aureus (MRSA). "
12/01/1991 - "An improved formulation of recombinant lysostaphin may prove to be an effective alternative to antibiotic therapy for bovine mastitis."
09/20/2001 - "A staphylococcal 145kDa cell wall adhesin, originally isolated from a bovine mastitis strain, was detected in lysostaphin-solubilized ovine mastitis strains and in the encapsulated strain A. "
03/01/2014 - "The presented results confirmed the observed worldwide problem of spreading antibiotic resistance among staphylococci isolated from bovine mastitis; on the other hand, we have indicated a high level of bactericidal activity of nisin and especially lysostaphin."
09/01/2014 - "The developed chitosan-protein scaffolds loaded with lysostaphin revealed high antistaphylococcal activity, which has been confirmed with a large (n = 143) collection of clinical (skin and wound infections) and animal (bovine mastitis) isolates of these bacteria, including MRSA. "
03/01/2014 - "The aim of this study was to analyze the resistance of Staphylococcus aureus isolates from bovine mastitis in the eastern part of Poland to a set of 20 antibiotics and three alternative agents: lysostaphin, nisin and polymyxin B. "
|5.||Anti-Bacterial Agents (Antibiotics)
|7.||Polymyxin B (Aerosporin)